Open AccessPhase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08
Author(s) -
Toshiki Masuishi,
Akihito Tsuji,
Masahito Kotaka,
Masato Nakamura,
Mitsugu Kochi,
Akinori Takagane,
Ken Shimada,
Tadamichi Denda,
Yoshihiko Segawa,
Hiroaki Tanioka,
Hiroki Hara,
Tamotsu Sagawa,
Takanori Watanabe,
Tsuyoshi Takahashi,
Yuji Negoro,
Dai Manaka,
Hideto Fujita,
Takeshi Suto,
Masahiro Takeuchi,
Wataru Ichikawa,
Masashi Fujii
Publication year - 2020
Publication title -
british journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.833
H-Index - 236
eISSN - 1532-1827
pISSN - 0007-0920
DOI - 10.1038/s41416-020-01042-w
Subject(s) - cetuximab , irinotecan , medicine , kras , colorectal cancer , oncology , regorafenib , clinical endpoint , progression free survival , confidence interval , randomized controlled trial , cancer , chemotherapy
Regorafenib or trifluridine/tipiracil as third-line treatment have limited efficacy in metastatic colorectal cancer (mCRC).